Viking Therapeutics, Inc.
- Open
- 39.50
- Day high
- 41.40
- Day low
- 38.95
- Prev close
- 39.54
- Volume
- 3.0M
- Mkt cap
- $4.5B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 9.0
- P/S
- —
- Yield
- —
- Per share
- —
Viking Therapeutics, Inc. (VKTX) is a Healthcare company listed on NASDAQ. The stock is up 46% over the past year. Drillr has 1 published research article covering VKTX.
Viking Therapeutics, Inc. (VKTX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
VKTX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 29, 2026 | $-1.01 | $-1.37 | -35.6% | — | — |
| Feb 11, 2026 | $-0.89 | $-1.38 | -55.1% | — | — |
| Oct 22, 2025 | $-0.70 | $-0.81 | -15.7% | — | — |
| Jul 23, 2025 | $-0.44 | $-0.58 | -31.8% | — | — |
| Apr 23, 2025 | $-0.34 | $-0.41 | -20.6% | — | — |
| Feb 5, 2025 | $-0.28 | $-0.32 | -14.3% | — | — |
| Oct 23, 2024 | $-0.24 | $-0.22 | +8.3% | — | — |
| Jul 24, 2024 | $-0.26 | $-0.20 | +23.1% | — | — |
| Feb 7, 2024 | $-0.25 | $-0.25 | +0.0% | $436000 | — |
| Oct 25, 2023 | $-0.22 | $-0.23 | -4.5% | — | — |
| Jul 26, 2023 | $-0.21 | $-0.19 | +9.5% | — | — |
| Feb 8, 2023 | $-0.23 | $-0.26 | -13.0% | — | — |
VKTX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 3, 2026 | Chen Hubert Cofficer: Chief Medical Officer | Grant | 190,000 | $31.27 |
| Mar 10, 2026 | Aubuchon Neil Williamofficer: Chief Commercial Officer | Buy | 4,475 | $33.50 |
| Jan 26, 2026 | Aubuchon Neil Williamofficer: Chief Commercial Officer | Grant | 180,000 | $31.76 |
| Jan 5, 2026 | Mancini Mariannaofficer: Chief Operating Officer | Sell | 1,600 | $35.07 |
| Jan 5, 2026 | Mancini Mariannaofficer: Chief Operating Officer | Sell | 13,600 | $33.37 |
| Jan 5, 2026 | Rowland Charles A Jrdirector | Grant | 3,150 | — |
| Jan 5, 2026 | Lian Briandirector, officer: President & CEO | Grant | 224,080 | — |
| Jan 5, 2026 | Lian Briandirector, officer: President & CEO | Grant | 78,400 | — |
| Jan 5, 2026 | Lian Briandirector, officer: President & CEO | Grant | 176,300 | $35.42 |
| Jan 5, 2026 | ZANTE GREGofficer: Chief Financial Officer | Sell | 13,900 | $33.38 |
| Jan 5, 2026 | Rowland Charles A Jrdirector | Grant | 20,400 | $35.42 |
| Jan 5, 2026 | ZANTE GREGofficer: Chief Financial Officer | Sell | 31,961 | $32.30 |
| Jan 5, 2026 | Mancini Mariannaofficer: Chief Operating Officer | Sell | 10,500 | $34.22 |
| Jan 5, 2026 | ZANTE GREGofficer: Chief Financial Officer | Grant | 41,000 | — |
| Jan 5, 2026 | Mancini Mariannaofficer: Chief Operating Officer | Grant | 41,000 | — |
Source: VKTX SEC Form 4 filings, latest Jun 3, 2026. For informational purposes only — not investment advice.
See the full VKTX insider & 13F page →VKTX research & analysis
Viking Therapeutics, Inc. company profile
Overview
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Diego, California. The company went public in 2015 and focuses on developing novel therapies for metabolic and endocrine disorders. Viking has emerged as a significant player in the obesity and metabolic disease treatment space, with multiple drug candidates in various stages of clinical development targeting conditions such as obesity, non-alcoholic steatohepatitis (NASH), and rare metabolic disorders.
Business
Viking Therapeutics operates in the biotechnology sector, specifically focusing on developing pharmaceutical treatments for metabolic and endocrine disorders. The company's business revolves around discovering, developing, and advancing drug candidates through clinical trials with the ultimate goal of bringing new treatments to market. The company's pipeline centers on several key therapeutic areas. VK2735 represents Viking's most advanced and promising program - a dual agonist that targets both GLP-1 and GIP receptors for obesity treatment. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are hormones that regulate blood sugar and appetite. By activating both receptors simultaneously, VK2735 aims to provide superior weight loss compared to existing single-mechanism treatments. The drug is being developed in both subcutaneous injection and oral tablet formulations. VK2809 targets non-alcoholic steatohepatitis (NASH), a serious liver condition where fat accumulates in the liver causing inflammation and potential scarring. NASH affects millions of people worldwide and currently has limited treatment options. VK2809 works as a thyroid hormone receptor beta (TRβ) agonist, which helps reduce liver fat and inflammation. The company also develops VK0214 for X-linked adrenoleukodystrophy (X-ALD), a rare genetic disorder that affects the nervous system and adrenal glands. Additionally, Viking has VK5211 in development for muscle wasting conditions and VK0612 for type 2 diabetes. A newer program involves developing an amylin receptor agonist, which could work as a standalone treatment or in combination with other obesity medications. Viking operates as a pure-play clinical-stage biotechnology company with no current revenue-generating products, as all candidates remain in clinical development phases.
Revenue model
Viking Therapeutics currently generates no revenue as it remains a clinical-stage company without any approved products. The company's business model is typical of biotechnology firms: it raises capital through equity offerings and uses these funds to advance drug candidates through expensive clinical trials, with the goal of eventually licensing or selling approved drugs to generate revenue. The company's primary funding sources include public equity offerings, with Viking raising over $630 million in 2024 alone. The company's future revenue model will likely involve multiple streams depending on how it commercializes its pipeline. For obesity treatments like VK2735, Viking could pursue direct commercialization in major markets, licensing deals with pharmaceutical partners, or a combination approach. The obesity market represents a massive commercial opportunity, with existing treatments like Ozempic and Wegovy generating billions in annual sales. For its NASH program VK2809, Viking is actively exploring partnership opportunities, which could involve upfront payments, milestone payments, and royalties on future sales. The rare disease program VK0214 for X-ALD might be suitable for orphan drug designation, potentially providing market exclusivity and premium pricing. Several factors will significantly impact Viking's future profitability. The competitive landscape in obesity treatments is intensifying, with multiple pharmaceutical giants developing competing therapies. Manufacturing costs for complex peptide drugs like VK2735 can be substantial, though economies of scale typically improve margins over time. Regulatory approval timelines and requirements will affect development costs and time to market. The company's ability to demonstrate superior efficacy and safety profiles compared to existing treatments will be crucial for market penetration and pricing power. Additionally, healthcare reimbursement policies for obesity treatments vary significantly and will influence market access and pricing strategies.
Competitive moat
Viking Therapeutics currently operates with limited competitive moats, which is typical for clinical-stage biotechnology companies. The company's primary potential advantages lie in its drug candidates' differentiated mechanisms of action and clinical profiles, though these remain unproven until regulatory approval and market launch. For VK2735, Viking's dual GLP-1/GIP receptor agonist showed promising Phase 2 results with up to 14.7% weight loss over 13 weeks. However, the obesity treatment space is highly competitive, with established players like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) already capturing significant market share. Viking's potential advantages include developing both subcutaneous and oral formulations, with the oral version potentially offering convenience benefits over injectable competitors. The company's intellectual property portfolio provides some protection, but biotechnology patents can be challenged and worked around by competitors. Viking's relatively small size compared to pharmaceutical giants means it has limited resources for extensive patent litigation or defensive strategies. Viking's main vulnerability stems from its dependence on clinical trial outcomes. A single negative Phase 3 result could severely impact the company's valuation and future prospects. The company also faces significant execution risk in scaling manufacturing, navigating regulatory processes, and competing against well-funded pharmaceutical companies with established commercial infrastructure. The competitive threat is substantial, as major pharmaceutical companies are actively developing next-generation obesity treatments, including combination therapies and novel mechanisms. Viking's window of opportunity may be limited if competitors reach market first with superior or equivalent treatments.
Risks & safety
Viking Therapeutics maintains a relatively strong financial position for a clinical-stage biotechnology company, though it faces typical biotech risks. • Cash Position: $903 million in cash and investments as of December 2024, providing substantial runway for operations • Burn Rate: Approximately $88 million annual cash burn (2024), suggesting roughly 10+ years of funding at current spending levels • Debt Level: Minimal debt with debt-to-equity ratio of 0.0013, indicating very low financial leverage • Current Ratio: Exceptionally strong at 33.1, demonstrating excellent short-term liquidity • Solvency Risk: Low near-term solvency risk given substantial cash reserves • Valuation Metrics: Price-to-book ratio of 5.0 suggests premium valuation relative to tangible assets • Enterprise Value: Negative EV/EBITDA due to losses, making traditional valuation metrics challenging • Market Expectations: Current valuation implies high expectations for clinical success • Other Considerations: Binary risk profile typical of clinical-stage biotech, with outcomes heavily dependent on Phase 3 trial results expected in 2025-2026. Strong balance sheet provides cushion for potential setbacks but doesn't eliminate execution risk.
Recent development
Over the past few years, Viking Therapeutics has transformed from a diversified clinical-stage company into an obesity-focused biotechnology firm with significant financial resources and advanced clinical programs. The most significant development has been the advancement of VK2735 for obesity treatment. The company completed a successful Phase 2 VENTURE trial showing up to 14.7% weight loss over 13 weeks, positioning Viking as a serious competitor in the lucrative obesity market. Management has aggressively expanded the program, developing both subcutaneous and oral formulations, with Phase 3 trials planned for Q2 2025. The company is also exploring monthly dosing regimens and potential combination therapies. Viking has strengthened its financial position dramatically, raising over $630 million in 2024, bringing total cash reserves to over $900 million. This war chest provides the company with resources to fund multiple large-scale Phase 3 trials and potential commercial preparation. The company has also advanced its NASH program VK2809, completing positive 52-week study results and conducting end-of-Phase 2 meetings with the FDA. However, Viking is now actively seeking partnership opportunities for this program, suggesting a strategic shift to focus resources on the obesity opportunity. Additional pipeline expansion includes the development of a new amylin receptor agonist program, which could serve as either a standalone obesity treatment or combination therapy. The company expects to file an IND and initiate Phase 1 trials for this program in 2025. Viking has also been building its organizational capabilities, expanding staff across multiple departments and working with external vendors to prepare for potential commercial-scale manufacturing and operations.
VKTX company profile · for informational purposes only — not investment advice.
Track VKTX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free